Jasper Therapeutics Inc(JSPR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.58 | Insider Own | 10.38% | Shs Outstand | 33.3M | Perf Week | 7.34% |
| Market Cap | 0.02B | Forward P/E | - | EPS next Y | -12.32% | Insider Trans | - | Shs Float | 29.8M | Perf Month | -8.28% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | -0.06 | Inst Own | 34.09% | Short Float | 21.71% | Perf Quarter | -15.56% |
| Income | -0.03B | P/S | - | EPS this Y | 88.35% | Inst Trans | - | Short Ratio | 13.07 | Perf Half Y | -43.16% |
| Sales | 0.00B | P/B | 10.57 | EPS next 5Y | 48.38% | ROA | -109.05% | Short Interest | 6.47M | Perf YTD | -70.93% |
| Book/sh | 0.05 | P/C | 2.29 | EPS past 3/5Y | 27.39% 48.97% | ROE | -255.05% | 52W High | -78.89% ($2.52) | Perf Year | -77.46% |
| Cash/sh | 0.23 | P/FCF | - | Sales past 3/5Y | - | ROIC | -2248.48% | 52W Low | 68.84% ($0.32) | Perf 3Y | -92.3% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 73.74% | Gross Margin | - | Volatility(W/M) | 10.35% 9.56% | Perf 5Y | -99.42% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.05 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.47 | EPS Q/Q | 94.48% | Profit Margin | - | RSI (14) | 46.7 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.47 | Sales Q/Q | - | SMA20 | 0.72% ($0.53) | Beta | 3.3 | Target Price | $9 |
| Payout | - | Debt/Eq | 0.19 | Earnings | 2026/8/14 | SMA50 | -12.1% ($0.6) | Rel Volume | 0.83 | Prev Close | $0.54 |
| Employees | 22 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 62.66% - | SMA200 | -37.94% ($0.85) | Avg Volume(3M) | 0.50M | Price | $0.53 |
| IPO | 2020/1/10 | Option/Short | Yes/Yes | Trades | 1094 | Volume | 413,083 | Change | -1.26% |
🧪 Jasper Therapeutics is a US clinical-stage biotech developing briquilimab, an anti-KIT (CD117) antibody that targets mast cell-related diseases. Its lead indications are chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma, and it is drawing attention for showing strong response rates in early-stage clinical trials. Listed on Nasdaq (), it is a micro-cap stock, with clinical events serving as the key driver of its value.
Over the past 1 year, on the lower side
79% below its 1-year high.
Traded about as much as usual. That is 83% of its average volume.
JSPR has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +88.3% this year.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.4%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
21.7% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #470 of 594 in the industry
Based on market cap of $18M.
CNTX#469 Context Therapeutics Inc $19M PER - JSPR#470 Jasper Therapeutics Inc $18M PER - 
RADX#471 Radiopharm Theranostics Ltd ADR $18M PER - 
AEON#472 AEON Biopharma Inc $17M PER - 
MRKR#473 Marker Therapeutics Inc $17M PER - 
FAQ
What kind of company is JSPR?
JSPR belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of JSPR?
The market cap of JSPR is approximately $18M, ranking 5,250 within its sector.
What is the 52-week high and low for JSPR?
JSPR has recorded a 52-week high of $2.52 and a low of $0.32.
